10 completed, 2 active not recruiting, 2 withdrawn. 8 Phase 1, 5 Phase 2, 3 Phase 3.
By phase and status
Follow NeuroDerm Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD - Parkinson's Disease | Phase 3 | Active not recruiting | NeuroDerm Ltd. | 381 | 2019-09-30 | 2025-05-21 |
A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
ND0612, CLES - Parkinson | Phase 3 | Withdrawn | NeuroDerm Ltd. | | 2018-04-10 | 2018-11-23 |
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
ND0612, Placebo - Parkinson's Disease | Phase 3 | Withdrawn | NeuroDerm Ltd. | | 2016-08-01 | 2019-12-10 |
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ND0612 - Parkinson's Disease | Phase 2 | Active not recruiting | NeuroDerm Ltd. | 214 | 2016-05-04 | 2025-05-30 |
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
ND0612 (Levodopa/Carbidopa solution), ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD - Parkinson's Disease | Phase 2 | Completed | NeuroDerm Ltd. | 38 | 2015-12-29 | 2023-05-25 |
A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects
ND0612, LCIG - Parkinson's Disease | Phase 1 | Completed | NeuroDerm Ltd. | 36 | 2015-05-29 | 2024-01-18 |
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
Levodopa/Carbidopa (Sinemet) - Parkinson's Disease | Phase 1 | Completed | NeuroDerm Ltd. | 6 | 2015-04-01 | 2015-07-01 |
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
LD/CD SC solution, Entacapone - Parkinson's Disease | Phase 1 | Completed | NeuroDerm Ltd. | 16 | 2014-08-11 | 2024-04-29 |
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ND0612, Placebo, Entacapone - Parkinson's Disease | Phase 2 | Completed | NeuroDerm Ltd. | 30 | 2014-01-06 | 2026-07-09 |
A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
Levodopa/carbidopa solution for SC administration, Placebo - Parkinson's Disease | Phase 1 | Completed | NeuroDerm Ltd. | 8 | 2012-12-16 | 2024-05-01 |
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
ND0612, Placebo - Parkinson's Disease | Phase 1 | Completed | NeuroDerm Ltd. | 36 | 2012-04-30 | 2024-01-18 |
A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients
Saline, Carbidopa - Parkinson's Disease | Phase 1 / Phase 2 | Completed | NeuroDerm Ltd. | 24 | 2011-01-01 | 2011-12-06 |
A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
ND0801 - Attention Deficit and Hyperactivity Disorder | Phase 1 / Phase 2 | Completed | NeuroDerm Ltd. | 40 | 2010-10-01 | 2019-12-05 |
Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611
ND0611 - Parkinson's Disease | Phase 1 | Completed | NeuroDerm Ltd. | 8 | 2010-04-01 | 2010-10-05 |
Conditions studied
Parkinson Disease (12) · Attention Deficit Disorder with Hyperactivity (1)
Interventions
Levodopa (5) · Sodium Chloride (3) · Carbidopa (2) · entacapone (2) · carbidopa, levodopa drug combination (1)
Countries
Israel (11) · Italy (4) · Austria (3) · United States (3) · Czechia (2) · France (2) · Poland (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Germany (1) · Hungary (1) · Netherlands (1) · Portugal (1) · Russia (1)
Top investigators
Laurence Salin, MD (2) · Alberto J Espay, MD, MSc (1) · Olivier Rascol, MD, PhD (1) · Osnat Ehrman (1) · Philip Evans, MBChB, MRCS (1) · Yoseph Caraco, MD (1)
Results publications
PMID 33164945, PMID 34496081, PMID 38499015